

**PVH TRANSLATE, LLC
BUSINESS TRANSLATION SAMPLES**

SALES AGREEMENT CONTRACT (French into English)

Commitments of Company

COMPANY promises to manufacture Products conform to Specifications.

COMPANY promises to manufacture and supply Products exempt of all aesthetic defects.

COMPANY promises to maintain upkeep of equipment necessary for the manufacture and packaging of the Products according to the rules of trade.

COMPANY promises to diligently accept and cooperate with all inspections required regarding the manufacture of the Products.

COMPANY will establish procedures to ensure application of the Specifications. **COMPANY** will be able to monitor adherence to the Specifications through audits performed at the **COMPANY** operation site. To this end and within the framework of quality assurance, **COMPANY** will allow **COMPANY** free entry into its workshops and plants.

COMPANY promises upon simple request to provide **COMPANY** with all organizational and technical documentation outlining quality standards as defined in the Specifications.

COMPANY promises to provide **COMPANY** within the shortest timeframes following receipt of samples, all necessary information in cases of claims, returns and recalls of Product lots. The replacement of defective products must occur within the shortest timeframe without foregoing the performance of required testing requirements.

For the duration of the present contract, **COMPANY** promises to establish for each Product a safety stock equal to a percentage of the total annual forecast figures. This percentage is outlined in annex 2 for each Product.

Cancellation of Contract

The present contract can be terminated by right and without official legal action in the case of non-performance of either party of the commitments and obligations contained within the clauses of this contract. This termination will become effective 30 days after the mailing of a registered letter along with proof of receipt outlining the reasons for the complaint, unless within this same time period, the faulty party has already fulfilled his obligations or provided evidence of non-performance related to an act of God/force of nature. Claiming the right to cancel does not exempt the faulty party however from fulfilling his contractual obligations up until the effective date of termination, and without prejudice to any recourse that may be taken against him by the other party. Subject to legal measures, the present contract can be terminated by right and without official legal proceedings by **COMPANY** in case of bankruptcy, liquidation, insolvency, judicial settlement or cessation of production operations on the part of **COMPANY**. Likewise, if one or several of the medicines manufactured by **COMPANY** containing in its formula one or several of the Product(s) was/were no longer being marketed/sold for whatever reason, this/these Product(s) would be automatically removed from this contract without any damage or interest owed in any way whatsoever by **COMPANY** towards **COMPANY**, with the exception of the repurchase of the safety stock that was established at **COMPANY**'s request.

SHARE PURCHASE AGREEMENT (French into English)

- 2.1** The Sellers hereby declare and guarantee that they hold and shall hold all of the Shares and the Equity Warrants on the Effective Date and that they have at this present date all powers, rights and authorizations necessary for the transfer of full ownership of the Shares and Equity Warrants to the Purchaser.
- 2.2** The Sellers hereby declare and guarantee that no rights attached to the Shares and to the Equity Warrants were transferred or could be exercised by any third party, for any reason whatsoever which could obstruct the sale of the Shares to the Purchaser or the full unrestricted enjoyment of the rights attached thereto. The exercise of the rights attached to the Shares and to the Equity Warrants are not subject, generally speaking, to any restriction other than those arising from the Company's by-laws or any applicable law.
- 2.3** The Sellers hereby declare and guarantee that the Shares and Equity Warrants are and shall be, on the Effective Date, validly and duly issued, and unencumbered by any financial obligations, rights, options, pledges or other guarantees, and that the Shares and Equity Warrants are freely transferable to the Purchaser.

6.1 Purchaser's Commitments

- 6.1.1** The Purchaser agrees to fulfill the following commitments towards each of the Sellers, beginning on the Effective Date until full payment of the Price Supplement is made:
- (a) To pledge to each Seller, as a collateral guarantee of its commitment to pay the Price Supplement, the account referred to in Annex C, held by the Company and in which the Shares shall be registered on the Effective Date; In the event of a transfer of Shares to a Related Company pursuant to article 5.4.5 above, the account(s) to which the transferred Shares are registered in the name of the transferee(s) shall be pledged in favor of each of the Sellers as a guarantee of the Purchaser's commitment to pay the Price Supplement. In the absence of such a pledge, any transfer of shares to a Related Company will be deemed null and void.
- (b) Not to reduce the issued share capital of the Company for any other reason than the reduction of capital owing to losses in the Company; to this end, the Purchaser commits to grant to the Sellers, with similar conditions to the pledge appended to the present Contract, a pledge relative to the issued shares newly subscribed by the Purchaser towards a recapitalizing of the Company due to the reduction of capital owing to losses in the Company;
- (c) To communicate to the Sellers, within 6 months after the end of the fiscal year, certified copies of the Company's annual balance sheet, profit and loss statements and related documents, as well as documents describing the Company's financial situation.

BANK FINANCING CONTRACT (Italian into English)

- a) The obligations deriving from this guarantee agreement are firm and indissoluble, even towards any successors or any future lawsuit for any reason,
- b) The guarantor can not withdraw from the course of operation of this guarantee agreement as long as it remains in effect until the complete fulfillment of the obligations guaranteed within.
- c) It is the guarantor's duty to keep abreast of the material conditions of the debtor and in particular to keep informed about the latter's relationship and dealings with BANK. Independently from what has been stated in the preceding subsection, BANK is required, however, by request of the guarantor, to communicate to him the extent of the obligation guaranteed, at the time of the request, as well as obtaining on behalf of the guarantor, by written consent from the principal debtor, additional information about the existing debt;
- d) The rights deriving from the guarantee to BANK are to remain intact until total payment of all amounts owed to the debtor, without requiring said debtor or guarantor to execute any other type of co-obligation or guarantee within the terms laid out by article 1957 of the Civil Code, hereby understood to be abrogated;

OIL/PIPELINE PROPOSAL & ENVIRONMENTAL IMPACT (Italian into English)

The GNL (liquefied natural gas at a temperature of 163° C), is transported by gas tanker ships containing thermally isolated tanks, consigned to the receiving Terminal where it is warehoused, regasified and transported to land via the pipeline to be then introduced into the distribution system. The measurement of gas introduced into the distribution system is performed in the gas reduction and measurement booth located on land, close to the connecting point between the on-land portion of the new pipeline and the national methane transport and distribution system - about 10 kilometers west of the landing point.

The Terminal is a structure made of concrete and resting on the seafloor; The anticipated location is in an area with a radius of 2.5 kilometers positioned about 10-12 kilometers off from the coast. Such an area is characterized by a morphologically flat bed, at a depth of 25-30 meters; The surface area directly occupied by the warehousing, processing systems and auxiliary equipment is about 30,000 square meters corresponding to the concrete platform's overall dimensions of around 356 x 56 meters, with the platform constructed from two modules; The test case that was conducted to verify the efficiency of the structure to protect against negative environmental impact anticipated during the operative phases, notably the adequacy of the system of docking and mooring to guard against environmental stress, was carried out on the LNC docked and moored ship, and came out with positive results; The estimated impact contained in the Study on Environmental Impact is generally agreed upon; The potential impact of the operation with regard to environmental change and/or disturbance would occur mainly during the construction phase of the Terminal and pipeline and concerns the re-suspension of sediment particles;

**CERTIFICATE OF ELECTRICAL COMPLIANCE FOR LEAK DETECTION SYSTEM
(English into French)**

DÉCLARATION DE CONFORMITÉ
SELON ISO/IEC GUIDE NO. 22
POUR UN SYSTÈME DE DÉTECTION DE FUITE-RÉCIPIENT

NORMES:

- Compatibilité Électromagnétique - Critère pour émissions génériques Partie 2: Environnement Industriel, EN50081-2, édition 1993
- Limites et méthodes de mensurations des caractéristiques de perturbation radioélectrique pour équipement industriel, scientifique, et médical (ISM), EN55011, édition 1998
- Compatibilité Électromagnétique (EMC) – Partie 6-2: Critères génériques – Immunité pour environnements industriels, EN61000-6-2, édition 1999
- Compatibilité Électromagnétique – Partie 4: Techniques d’essai et de mesure – Section 2: Essai d’immunité pour décharge électrostatique, EN 61000-4-2, édition 1995
- Compatibilité Électromagnétique – Partie 4: Techniques d’essai et de mesure – Section 3: Essai d’immunité pour puissance rayonnée, radiofréquence, et champ électromagnétique, EN 61000-4-3, édition 1995

PROFIT & LOSS STATEMENT (Italian into English)

PRODUCTION VALUE & COSTS	CURRENT YEAR	PREVIOUS YEAR
--------------------------	--------------	---------------

Sales and/or Services Rendered (Revenues)
Leftover Stock Variations (Finished or Semi-Finished Products)
Variations in Unfinished Work Made to Order
Increases in Fixed Assets (for in-house work)
Other Revenues and Proceeds
Contributions to Fiscal Year Account

A) TOTAL VALUE OF PRODUCTION

Raw Materials, Subsidiaries, Consumer Merchandise, Goods & Services
Enjoyment of Third Party Goods & Property
Salaries & Stipends
Social Costs
Work Severance Pay
Retirement Package Pay
Other Costs

TOTAL PERSONNEL COSTS

Depreciation on Fixed Intangible Assets
Depreciation on Fixed Tangible Assets
Fixed Assets Devaluations

Credit Devaluations (included in Current Assets)

TOTAL DEPRECIATION AND/OR DEVALUATIONS

Variations in Stock, Raw Materials, Subsidiaries, etc.
Appropriated Risk Funds
Other Appropriations
Various Management Costs

RM LEFT KNEE (Italian into English)

Technique: Sequences of SE T1-w on Sagittal and Coronal planes;
SE-ME DP-w and T2-w on Sagittal plane

The exam which was performed without paramagnetic mdc infusion showed:

No reportable signs of bony lesions “underway” or already established of a traumatic type on skeletal components examined.

Regular signal from adipose cells of the Hoffa bursa.

Signs of reactive synovitis with stretched joint capsule from the presence of heavy free effusion located in the intrarticular and pararticular area; visibility of a subtle medial patellar synovial fold.

Menisci cartilages are within normal limits relative to morphology and signal.

The anterior cruciate ligament appears thinned out and evidences ill-defined margins and a slightly inhomogeneous signal, as results from partial laceration.

The external collateral ligament appears thickened and evidences ill-defined margins and an inhomogeneous signal, due to partial post-laceration inflammation.

The posterior and medial collateral ligaments as well as the patellar tendon are within normal limits relative to caliber and signal.

The patellar-femur axis is within normal limits.

RX CERVICAL VERTEBRAL COLUMN, CHEST, PELVIS, LEFT KNEE

Inverted cervical lordosis.

No visible bony lesions to report on established fractures in skeletal segments examined.

No signs of established infiltrating pleuroparenchymal lesions. Regular diaphragm in the profile with open lateral costophrenic sinuses. Cardiac shadow within normal volumetric limits.

ABDOMEN ULTRASOUND

No structural changes are visible presently of a traumatic nature of the parenchymatous abdominal organs nor is there any free endoperitoneal effusion visible.

CT CRANIUM AND FACIAL MASS SMDC EV

Ventricular system in axis; of regular amplitude.

Normal amplitude of pericerebral liquor grooves.

No densitometric changes are visible of a traumatic origin of intracranial structures.

There are no visible osteotraumatic lesions of the cranial theca.

Fracture of the nasal bones with decomposition into fragments at the root of the nose; fracture of the anterior slope of the nasal septum with dislocated anterior fragments on the left and deviation of the same on the right-convex. Mucous congestion of crescent-shaped nasal markings.

Modest subcutaneous hematoma of the left palpebral region with tiny gas nuclei of loco regional subcutaneous emphysema. The paranasal passages are open.

**DECLARATION OF INFORMED CONSENT REGARDING ANASTHESIA, SURGERY,
BLOOD COMPONENTS, BLOOD DERIVATIVES AND OTHER PROCEDURES.**

(Italian into English)

The nature and scope of the operation and/or test, possible alternative methods or possible complications have been fully and clearly explained to me. I am fully aware that I have not been given any kind of guarantee concerning the outcome of the operation or procedure. The type of surgery or diagnostic test planned is: _____.

I have also been informed that for such a surgical procedure and owing to my particular circumstances, a transfusion of blood or blood derivative may be necessary. It has been explained to me that I may donate my own blood which would then be transfused back to me during the operation thus reducing the recognized risks of blood usage. (Erase this section if not planned or anticipated).

I accept the execution of the above-mentioned operation and/or test and any other further procedure that could become necessary or desirable in the judgment of the members of the operating unit team during the course of the described operation and/or test. I also accept that in case of necessity blood and/or blood derivatives may be administered to me.

I accept and agree to the following type of anesthesia which is considered necessary or preferable according to the opinion of the anesthesiologist from whom I have received an exhaustive explanation _____.

CLINICAL LAB REPORTS (Italian into English)

CHEMICAL LAB ANALYSIS

Glucose (UV-Enzymatic) Urea (GLDH/Ureasi) Creatinine (Jaffe with white synthetic)
Total Bilirubin (DPD) Direct Bilirubin (Jendrassik mod.) Indirect Bilirubin Iron (Serochrome)
CPK (UV-Enzymatic) GOT/AST (IFCC 37 °) GPT/ALT Calcium (Serochrome) Magnesium
(Serochrome) Phosphorous (UV-Molibdated) Chlorine (Indirect ISE) Sodium (Indirect ISE)
Potassium (Indirect ISE) PCR (Turbidimetry)

HEMATOLOGY

Complete Blood Count (Sysmex SF3000) White Blood Cells Red Blood Cells Hemoglobin
Blood Volume Measurement MCV (Average Global Volume) MCH (Avg. Hemoglobin Corpusc.) MCHC
(Avg. Conc. Hemgl. Corpusc.) Platelets RDW-SD (Eryth. Dispersion Index)
RDW-CV (Eryth. Variability Index) MPV (Average Platelet Volume) P-LCR (Large Platelets Percentage)
Leukocytic Formula (Sysmex SF3000) Neutrophils Lymphocytes Monocytes

CHEMICAL COMPOUND PATENT APPLICATION (French into English)

In the previous article, different substances have been described, notably peptides demonstrating antimicrobial properties, most particularly demonstrating bactericidal or fungicidal properties. Opportunistic microorganisms first target immunodepressed/immunocompromised subjects, in which they can develop into pathogens, more often than not resistant. Immunosuppression can be the result of a variety of causes such as for example corticotherapy, chemotherapy, transplants or grafts or infection with the HIV virus.

Thus, the research activities performed relative to this invention entailed synthesizing variants of the harmonine that could demonstrate not only improved antimicrobial activity but that were also non-toxic towards blood cells. A structure-activity analysis enabled the applicant (inventor) to conceptualize, then synthesize compounds more favorable pharmacologically and having more compactness in structure. The compounds in this invention offer a rigidified framework through a cycle that makes the compounds compact and reduces the degree of freedom of rotation around sigma bonds.